MAPK3 and cancer: The extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, a pivotal effector of the RAS-RAF-MEK-ERK cascade, is aberrantly activated in a substantial proportion (~40-60%) of human cancers through context-dependent mechanisms (32).